Related Experiment Videos
Replicating vectors for gene therapy of cancer: risks, limitations and prospects
1Cambridge Centre for Protein Engineering, MRC Centre, UK.
Abstract:
There are good theoretical arguments for exploring the use of replicating gene-transfer vectors for human cancer therapy. Such vectors should be derived from weakly pathogenic human viruses with initially broad tissue tropism. Coat protein engineering and promoter engineering might be used successfully to narrow the tropism of the vector, enhancing its ability to target tumour cells. Killing of uninfected 'bystander' tumour cells could be achieved through prodrug activation by a vector-encoded enzyme. Rapid elimination of infused vector particles by circulating antiviral antibody would limit access to tumour deposits after repeated administration, but might be circumvented by the use of infectious nucleic acid which is poorly imunogenic [64]. This putative therapeutic strategy is illustrated in Figure 1.
Insights
Replicating gene-transfer vectors show promise for cancer therapy by targeting tumor cells and killing bystander cells. Engineering vectors and using infectious nucleic acids may overcome challenges like immune response for effective treatment.
Area of Science:
- Oncolytic virology
- Gene therapy
- Viral vector engineering
Background:
- Gene-transfer vectors are being explored for human cancer therapy.
- Replicating vectors derived from weakly pathogenic human viruses with broad tropism are considered.
- Challenges include targeting specificity and immune response to repeated administration.
Purpose of the Study:
- To explore the theoretical basis for using replicating gene-transfer vectors in human cancer therapy.
- To outline strategies for enhancing vector tumor-targeting capabilities.
- To address potential limitations such as immune elimination of vector particles.
Main Methods:
- Theoretical exploration of viral vector design principles.
- Coat protein and promoter engineering for tropism modification.
- Prodrug activation strategies for bystander cell killing.
- Consideration of infectious nucleic acid to evade immune responses.
Main Results:
- Engineering can narrow vector tropism, improving tumor cell targeting.
- Vector-encoded enzymes can activate prodrugs to kill bystander tumor cells.
- Infectious nucleic acids may circumvent immune elimination of vector particles during repeated administration.
Conclusions:
- Replicating gene-transfer vectors offer a promising theoretical strategy for cancer therapy.
- Vector engineering and prodrug activation are key to enhancing efficacy and safety.
- Overcoming immune responses is crucial for successful repeated administration of gene-transfer vectors.